Yang leads a Health Economics and Outcomes Research (HEOR) consulting team that focuses on health economic modeling and analytics, especially for the US market, and global models for US-based pharmaceutical companies.
Yang has over 20 years of experience in health economic modeling spanning academia (including University of Sheffield and University of Warwick) and HEOR consultancy. Yang has led a range of modeling and HEOR projects including health technology assessment (HTA) submissions/assessments for the National Institute for Health and Care Excellence (NICE), US Institute for Clinical and Economic Review (ICER), Canada’s Drug Agency (CDA-AMC)/Institut national d’excellence en santé et en services sociaux (INESSS), and the Scottish Medicines Consortium (SMC), and HTA bodies in Australia, Spain, Italy, France, Belgium, Sweden, Japan, and China.
Yang has a core technical skill set covering cost-effectiveness, budget impact, cost-minimization and disease pathway models, model conceptualization, survival modeling, econometrics, patient-level data analysis, and public health modeling. Yang’s experience in disease areas include oncology (e.g. bladder, prostate, esophageal, gastric, lung, melanoma, non-Hodgkin’s lymphoma, and pan-indication), diagnostics of cancers, hepatitis C, mental health, infectious disease, and alcohol/addiction.
Yang has published widely in health economics, HTA, and alcohol/addiction research in top medical and health economics journals, including The Lancet, BMJ, Health Economics, the Journal of Health Economics, and Addiction.
Yang holds a PhD in Healthcare Modeling & Simulation and an MSc in Management Science & Operational Research from the University of Warwick, UK.